213 related articles for article (PubMed ID: 31634730)
1. Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
3. Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer.
McKendrick JJ; Mead GM; Cowlishaw D
Clin Oncol (R Coll Radiol); 2003 May; 15(3):128-31. PubMed ID: 12801050
[No Abstract] [Full Text] [Related]
4. Topoisomerase II alpha expression in testicular germ cell tumors.
Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors.
Voss MH; Feldman DR
Onkologie; 2011; 34(8-9):410-1. PubMed ID: 21934338
[No Abstract] [Full Text] [Related]
6. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
7. Current Management of Refractory Germ Cell Tumors.
Abughanimeh O; Teply BA
Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
[TBL] [Abstract][Full Text] [Related]
8. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
10. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
11. Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets.
Chieffi P; De Martino M; Esposito F
Expert Rev Anticancer Ther; 2020 Mar; 20(3):189-195. PubMed ID: 32164473
[No Abstract] [Full Text] [Related]
12. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
Calaminus G; Schneider DT; Weissbach L; Schönberger S; Okpanyi V; Leuschner I; Poremba C; Göbel U
Klin Padiatr; 2009; 221(3):136-40. PubMed ID: 19437360
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
Culine S; Theodore C; Court BH; Perrin JL; Droz JP
Br J Urol; 1997 Feb; 79(2):258-62. PubMed ID: 9052479
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
15. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation.
Loehrer PJ; Hui S; Clark S; Seal M; Einhorn LH; Williams SD; Ulbright T; Mandelbaum I; Rowland R; Donohue JP
J Urol; 1986 Jun; 135(6):1183-9. PubMed ID: 2423708
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
17. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
[TBL] [Abstract][Full Text] [Related]
18. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
19. Cancer of the testis: a new paradigm.
Einhorn LH
Hosp Pract (Off Ed); 1986 Apr; 21(4):165-72, 175-8. PubMed ID: 2420812
[No Abstract] [Full Text] [Related]
20. [Chemotherapeutic effectiveness in malignant testicular tumors at advanced stages. Preliminary results of the VAB VI program].
Chiricuţă I; Ghilezan N
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1985; 34(6):455-68. PubMed ID: 2421373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
